Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas

Novartis AG (NYSE:NVS) is one of the top gene therapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) announced on February 25 plans to establish a new 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas. It stated that the purpose-built RLT site would mark the company’s fifth in the United States and first manufacturing facility in Texas, and reflects further progress in its $23 billion US investment. Construction is scheduled to begin in 2026, and the site is anticip ...